Efavirenz 400 vs 600 mg combined with lamivudine and tenofovir in treatment-naïve HIV-infected patients in China: A randomized, multi-centered, controlled trial
InfectologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
- Publicado em
- 2 jun 2026
- Citações
- 1
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Efavirenz 400 vs 600 mg combined with lamivudine and tenofovir in treatment-naïve HIV-infected patients in China: A randomized, multi-centered, controlled trial
Qi Hang, Wang Ziyan, Song Xiaojing, Wang Min, Ding Haibo, Ye Hanhui, Meng Zhihao, He Shenghua, He Yun, Li Linghua et al.
Descritores MeSH
- Tenofovir
- HIV Infections
- Lamivudine
- Anti-HIV Agents
- Benzoxazines
- Drug Therapy, Combination
- Female
- Humans
- Male
- Middle Aged
Veja também
Estudos relacionados
- Safety of low dose efavirenz regimen in Indian adults with HIV-1 infection: Insights from a phase 4 interventional randomised trial
- Rapid Initiation of Antiretroviral Therapy With Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Versus Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate in HIV-Positive Men Who Have Sex With Men in China: Week 48 Results of the Multicenter, Randomized Clinical Trial
- Efficacy and safety of TDF+3TC + EFV‑centric antiretroviral regimens for HIV/HBV co-infection: a systematic review and network meta‑analysis
- Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study